Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Immunotherapy is offering patients with cancer new therapy options. Here, the authors report on the crystal structures of some of these therapies bound to their targets.
Main Authors: | Ju Yeon Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee, Seong Eon Ryu, Ji Young Son, Jee Un Lee, Yong-Seok Heo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms13354 |
Similar Items
-
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01) -
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
by: Heejin Lim, et al.
Published: (2018-03-01) -
BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
by: Woori Shin, et al.
Published: (2018-03-01) -
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01) -
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)